Advanced Cancer Pain Management (ACPM) - Pipeline Insight - 2020
This report can be delivered to the clients within 24-48 Hours
DelveInsight’s, “Advanced Cancer Pain Management (ACPM) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Advanced Cancer Pain Management (ACPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Advanced Cancer Pain Management (ACPM): Overview
Advanced Cancer Pain is the pain most commonly experienced and feared by patients with advanced cancer, during their treatment. Pain in a cancer patient is a subjective, multi-dimensional human experience, with complex interactions between sensory and emotional components. Twenty to 34 percent of patients have severe pain, which directly influences their quality of life and daily function (i.e., pain interference). Solid tumors produce more pain than leukemias and lymphomas. Most cancer patients experience pain, usually of moderate to severe intensity, and most also have a number of distinct pains. The most common type of pain is related to bone metastases. Neuropathic pain occurs in one-third of patients, alone, or as a mix of nociceptive and neuropathic pain. An effective pain management is a priority in the palliative care of advanced cancer patients where quality of life is adversely affected by total pain.
Assessesment
A comprehensive assessment of cancer pain is one of the most essential components for its successful management. Cancer pain is multidimensional in nature and other factors like physiological, psychological and social conditions must be considered. A thorough medical review including the type of cancer, the stage, sites of involvement, previous therapies and their effects, planned therapies in the future, other co morbidities, organ dysfunction can provide specific options for management of the pain.
Treatment
The WHO recognizes the importance of pain management as a part of routine cancer care. An effective pain management requires comprehensive assessment, competency with analgesics, and communication with patients and their families. Non-opioids, opioids like Morphine, and adjuvant analgesics are the available cancer pain management treatments. Drugs like fentanyl, buprenorphine, hydromorphone, and oxycodone with advanced delivery systems have increased advantages over morphine. The failure to manage pain properly is due to several factors like limited resources, lack of physician education and failure to follow existing guidelines, fear of addiction, drug tolerance, and side effects.
Advanced Cancer Pain Management (ACPM) Emerging Drugs Chapters
This segment of the Advanced Cancer Pain Management (ACPM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Cancer Pain Management (ACPM) Emerging Drugs
Further product details are provided in the report……..
Advanced Cancer Pain Management (ACPM): Therapeutic Assessment
This segment of the report provides insights about the different Advanced Cancer Pain Management (ACPM) drugs segregated based on following parameters that define the scope of the report, such as:
Advanced Cancer Pain Management (ACPM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cancer Pain Management (ACPM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cancer Pain Management (ACPM) drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Advanced Cancer Pain Management (ACPM) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Advanced Cancer Pain Management (ACPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Advanced Cancer Pain Management (ACPM): Overview
Advanced Cancer Pain is the pain most commonly experienced and feared by patients with advanced cancer, during their treatment. Pain in a cancer patient is a subjective, multi-dimensional human experience, with complex interactions between sensory and emotional components. Twenty to 34 percent of patients have severe pain, which directly influences their quality of life and daily function (i.e., pain interference). Solid tumors produce more pain than leukemias and lymphomas. Most cancer patients experience pain, usually of moderate to severe intensity, and most also have a number of distinct pains. The most common type of pain is related to bone metastases. Neuropathic pain occurs in one-third of patients, alone, or as a mix of nociceptive and neuropathic pain. An effective pain management is a priority in the palliative care of advanced cancer patients where quality of life is adversely affected by total pain.
Assessesment
A comprehensive assessment of cancer pain is one of the most essential components for its successful management. Cancer pain is multidimensional in nature and other factors like physiological, psychological and social conditions must be considered. A thorough medical review including the type of cancer, the stage, sites of involvement, previous therapies and their effects, planned therapies in the future, other co morbidities, organ dysfunction can provide specific options for management of the pain.
Treatment
The WHO recognizes the importance of pain management as a part of routine cancer care. An effective pain management requires comprehensive assessment, competency with analgesics, and communication with patients and their families. Non-opioids, opioids like Morphine, and adjuvant analgesics are the available cancer pain management treatments. Drugs like fentanyl, buprenorphine, hydromorphone, and oxycodone with advanced delivery systems have increased advantages over morphine. The failure to manage pain properly is due to several factors like limited resources, lack of physician education and failure to follow existing guidelines, fear of addiction, drug tolerance, and side effects.
Advanced Cancer Pain Management (ACPM) Emerging Drugs Chapters
This segment of the Advanced Cancer Pain Management (ACPM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Cancer Pain Management (ACPM) Emerging Drugs
- QIXLEEF: Tetra Bio-Pharma
- NanaBis: Medlab
Further product details are provided in the report……..
Advanced Cancer Pain Management (ACPM): Therapeutic Assessment
This segment of the report provides insights about the different Advanced Cancer Pain Management (ACPM) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Cancer Pain Management (ACPM)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Advanced Cancer Pain Management (ACPM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cancer Pain Management (ACPM) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cancer Pain Management (ACPM) drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cancer Pain Management (ACPM) R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Cancer Pain Management (ACPM).
- Medlab Clinical Ltd (ASX:MDC) has entered into an agreement with Canadian pharmaceutical company, Pharmascience Inc. for the further development and global distribution of its NanaBis.
- Advanced Cancer Pain Management (ACPM) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Cancer Pain Management (ACPM) drugs?
- How many Advanced Cancer Pain Management (ACPM) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Cancer Pain Management (ACPM)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Cancer Pain Management (ACPM) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Cancer Pain Management (ACPM) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tetra Bio-Pharma
- Medlab
- Sorrento Therapeutics, Inc.
- Pfizer
- QIXLEEF
- NanaBis
- Resiniferatoxin
- Tanezumab
Introduction
Executive Summary
Advanced Cancer Pain Management (ACPM): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Cancer Pain Management (ACPM) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced Cancer Pain Management (ACPM) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Advanced Cancer Pain Management (ACPM) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
QIXLEEF: Tetra Bio-Pharma
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
NanaBis: Medlab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced Cancer Pain Management (ACPM) Key Companies
Advanced Cancer Pain Management (ACPM) Key Products
Advanced Cancer Pain Management (ACPM)- Unmet Needs
Advanced Cancer Pain Management (ACPM)- Market Drivers and Barriers
Advanced Cancer Pain Management (ACPM)- Future Perspectives and Conclusion
Advanced Cancer Pain Management (ACPM) Analyst Views
Advanced Cancer Pain Management (ACPM) Key Companies
Appendix
Executive Summary
Advanced Cancer Pain Management (ACPM): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Cancer Pain Management (ACPM) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced Cancer Pain Management (ACPM) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Advanced Cancer Pain Management (ACPM) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
QIXLEEF: Tetra Bio-Pharma
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
NanaBis: Medlab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced Cancer Pain Management (ACPM) Key Companies
Advanced Cancer Pain Management (ACPM) Key Products
Advanced Cancer Pain Management (ACPM)- Unmet Needs
Advanced Cancer Pain Management (ACPM)- Market Drivers and Barriers
Advanced Cancer Pain Management (ACPM)- Future Perspectives and Conclusion
Advanced Cancer Pain Management (ACPM) Analyst Views
Advanced Cancer Pain Management (ACPM) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Advanced Cancer Pain Management (ACPM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Advanced Cancer Pain Management (ACPM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Advanced Cancer Pain Management (ACPM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Advanced Cancer Pain Management (ACPM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products